germany program - drfalkpharma.com · beuers, amsterdam; a . parés, barcelona 16.30 fatigue in pbc...

Program

P197

e 1-

4/2

015

/90

0 St

ü

General Information:

FALK FOUNDATION e.V.Leinenweberstr. 579108 FreiburgGermany

Congress DepartmentTelephone: +49(0)761/1514-0Telefax: +49(0)761/1514-359E-Mail: [email protected]

Falk Symposium 197

Autoimmune Diseases of the Liver

May 8 – 9, 2015Estoril Centro de CongressosLisbon, Portugal

CME credits 9

Awarded with

113988_Falk_Lissabon_Symp197_Prog_UG.indd 1 14.04.15 15:07

3

Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4

Scientific Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6

Posters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9

List of Speakers, Moderators and Scientific Organizers . . . . . . . . . . . . . . . . . . . . . . . . 16

Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19

9 credit hours (CME) have been awarded for the Falk Symposium 197 by the European Union of Medical Specialists (UEMS) - European Board of Gastroenterology (EBG) .

113988_Falk_Lissabon_Symp197_Prog_Inhalt.indd 3 14.04.15 15:15

4

Preface

Dear Colleagues,

Chronic diseases of the liver are among the most common chronic conditions worldwide . There is a lower awareness of chronic liver diseases compared to other types of chronic diseases, such as those affecting the lungs, heart, kidneys or joints . Furthermore the importance of chronic liver diseases as a health issue has been underestimated . In fact, recent epidemiological studies performed in a large number of countries around the world have shown that cirrhosis ranks among the top ten causes of death and the importance of hepatocellular carcinoma, which is almost always associated with cirrhosis, is increasing at a fast rate .

Among the etiological causes of chronic liver diseases, the frequency of autoimmune liver diseases is increasing markedly, particularly in western countries . The current symposium is devoted to “Autoimmune Diseases of the Liver” and will be divided in four different parts: an introductory part chaired by Prof . Cortez-Pinto (Lisbon) that will discuss miscellaneous issues and three parts devoted to the main autoimmune diseases of the liver: Autoimmne Hepatitis chaired by Prof . Ansgar Lohse (Hamburg); Primary Biliary Cirrhosis chaired by Prof . Albert Parés (Barcelona) and Sclerosing Cholangitis chaired by Prof . Ulrich Beuers (Amsterdam) . In these three parts, the main issues related to each of the diseases will be discussed in depth by world renowned experts followed by active discussions .

Given the growing interest of the field of Autoimmune Liver Diseases and the excellent panel of speakers, the scientific organizers hope that the program will attract your interest . We look forward to welcoming you to the beautiful city of Lisbon on the occasion of the Falk Symposium 197 on Autoimmune Diseases of the Liver .

On behalf of the Scientific Organizers,

Pere Ginès


5

Falk Symposium 197



Registration:Thursday, May 7, 201516 .00 – 21 .00 hat the congress office

Scientific Organization:U . Beuers, Amsterdam (The Netherlands)H . Cortez-Pinto, Lisbon (Portugal)P . Ginès, Barcelona (Spain)A . W . Lohse, Hamburg (Germany)A . Parés, Barcelona (Spain)

Congress Venue:Estoril Centro de CongressosAvenida Amaral2765-192 EstorilPortugal

Information:Prof . Dr . Pere GinèsChairman, Liver UnitUniversity of BarcelonaHospital Clinicc/ Villarroel no . 17008036 BarcelonaSpainTelephone: +34 93 / 227 17 13Telefax: +34 93 / 227 17 79E-Mail: pgines@clinic .ub .es

Official Language:English

Posters:A poster session will take place .For details see page 9 .


6

Friday, May 8, 2015

9.00 Welcome P . Ginès, Barcelona

Session I Introduction

Chair: H . Cortez-Pinto, Lisbon; P . Ginès, Barcelona

9.05 Worldwide incidence of autoimmune liver diseases P . Jepsen, Aarhus

9.30 Are there common genetic factors among the three T . H . Karlsen, autoimmune liver diseases? Oslo

9.55 Extrahepatic manifestations associated with M . A . Heneghan, autoimmune hepatitis London

10.20 Pediatric autoimmune liver diseases R . Liberal, London

10.45 Coffee break with poster session

Session II Autoimmune hepatitis

Chair: A . W . Lohse, Hamburg; A . Parés, Barcelona

11.15 Diagnostic criteria: Scores and more A . W . Lohse, Hamburg

11.40 Role of histopathology: What is typical for, what is D . G . Tiniakos, compatible with AIH? Newcastle upon Tyne

12.05 Autoantibodies in autoimmune hepatitis: L . Muratori, Which ones, with what tests, how often? Bologna

12.30 Autoimmune hepatitis: From pathogenesis to novel J . Herkel, immune therapies Hamburg

12.55 Lunch break with poster session


7

Friday, May 8, 2015

Session II (cont) Autoimmune hepatitis / Primary biliary cirrhosis

Chair: A . W . Lohse, Hamburg; A . Parés, Barcelona

13.55 Standard treatment in adults: Which steroids? D . C . Gleeson, Or without steroids? Sheffield

14.20 Which alternative for difficult to treat patients? C . Schramm, Hamburg

14.45 Geoepidemiology, genetic and environmental risk P . Invernizzi, factors for PBC Rozzano

15.10 The immunobiology and pathophysiology of PBC G . Hirschfield, Birmingham

15.35 Treatment of autoimmune hepatitis: G . Bouma, Should we ever stop? Amsterdam


Session III Primary biliary cirrhosis

Chair: U . Beuers, Amsterdam; A . Parés, Barcelona

16.30 Fatigue in PBC . Prevalence, pathogenesis and D . E . J . Jones, management Newcastle upon Tyne

16.55 Non-invasive assessment of liver fibrosis progression R . Poupon, and prognosis in PBC Paris

17.20 Surrogate markers for optimal therapeutic response H . R . van Buuren, to UDCA Rotterdam

17.45 Novel approaches for patients with suboptimal A . Parés, response to UDCA Barcelona

18.10 End of afternoon session


8

Saturday, May 9, 2015

Session IV Primary sclerosing cholangitis

Chair: U . Beuers, Amsterdam; H . Cortez-Pinto, Lisbon

9.30 Diagnosis, differential diagnosis and epidemiology of PSC C . Y . Ponsioen, Amsterdam

9.55 Genetic Factors: Their role in pathogenesis of PSC A . Franke, Kiel

10.20 Immunopathology of PSC D . H . Adams, Birmingham

10.45 Malignancies in PSC – a continuing threat L . Fabris, Padova


11.40 Presentation of poster prizes P . Ginès, Barcelona

U . Beuers, Amsterdam

Session IV (cont) Primary sclerosing cholangitis

Chair: U . Beuers, Amsterdam; P . Ginès, Barcelona

11.50 Therapy of PSC today and tomorrow M . Trauner, Vienna

12.15 Pathogenesis and management of pruritus in PBC and PSC A . E . Kremer, Erlangen

12.40 IgG4-associated cholangitis: A mimic of PSC U . Beuers, Amsterdam

13.05 Overlap syndromes O . Chazoullières, Paris

13.30 Farewell Lunch


9

Poster SessionPosters will be exhibited on May 8-9, 2015 in the Estoril Centro de Congressos in Estoril/Lisbon . The authors will be in attendance during coffee and lunch breaks on both days .

PBC1 . Non-invasive assessment of disease stage in patients with primary biliary cirrhosis N . Ben Mustapha, M . Mahmoudi, M . Amri, R . Ben Jemaa, M . Fekih, L . Kallel,

M . Serghini, S . Matri, J . Boubaker, A . Filali (Tunis, TN)

2 .* The UK-PBC Risk Score: Derivation and validation of a risk score to predict liver events in PBC M . Carbone, S . Sharp, M .A . Heneghan, G . Hirschfield, J . Neuberger, A .K . Burroughs, D . Thorburn, A . Bathgate, M . Aldersley, C . Adgey, P . Trumbling, K . Williamson, L . Jopson, R . Lim, N .J . Wareham, H . Cordell, G .J . Alexander, D .E .J . Jones, R .N . Sandford, G .F . Mells; UK-PBC Consortium (Cambridge, London, Birmingham, Edinburgh, Newcastle upon Tyne, GB)

3 . The role of peripheral blood Treg and Th17 cells in primary biliary cirrhosis H . Cichoz-Lach, E . Grywalska, A . Kowalik, J . Rolinski, K . Celinski (Lublin, PL)

4 . Primary biliary cirrhosis: Clinical characteristics and treatment response D . Dukova, I . Ivanova, I .A . Kotzev (Varna, BG)

5 . The impact of age at presentation on symptoms in primary biliary cirrhosis J . Dyson, L . Jopson, S . Ducker, G . Mells, R . Sandford, D .E .J . Jones (Newcastle upon Tyne, Cambridge, GB)

6 . Age at presentation and gender are predictors of increased mortality over long-term follow-up in primary biliary cirrhosis J . Dyson, L . Jopson, S . Ducker, D .E .J . Jones (Newcastle upon Tyne, GB)

7 . Alternative to liver biopsy in primary biliary cirrhosis: Non-invasive serum markers of liver fibrosis E . Gravito-Soares, M . Gravito-Soares, C . Lerias, S . Lopes, C .M .R . Sofia (Coimbra, PT)

8 . Is primary biliary cirrhosis a systemic disease? Cardiovascular risk assessment M . Gravito-Soares, E . Gravito-Soares, C . Agostinho, D . Gomes, P . Figueiredo, L . Tome, C .M .R . Sofia (Coimbra, PT)

9 . Antimitochondrial antibody-negative primary biliary cirrhosis: A different entity? M . Gravito-Soares, E . Gravito-Soares, S . Lopes, C . Agostinho, D . Gomes, P . Figueiredo, L . Tome, C . Sofia (Coimbra, PT)

10 . Expression of IL-17 and IgG4 in portal tracts in primary biliary cirrhosis M .V . Gulubova, K . Ivanova, J . Ananiev, M .M . Iganatova (Stara Zagora, BG)

11 .* Risk factors for hepatic decompensation in primary biliary cirrhosis – Results of an international follow-up study of 2326 patients . M .H . Harms, W .J . Lammers, P . Invernizzi, P .M . Battezzati, A .R . Floreani, A . Pares, F . Nevens, D . Thorburn, A .L . Mason, K .V . Kowdley, C . Ponsioen, C . Corpechot, H .L .A . Janssen, G . Hirschfield, M . Mayo, N .F . LaRusso, A . Lleo, N . Cazzagon,


10

I . Franceschet, L . Caballeria, R . Poupon, A . Cheung, P . Trivedi, K .D . Lindor, H .R . van Buuren, B .E . Hansen; Global PBC Study Group (Rotterdam, Amsterdam,NL; Rozzano, Milan, Padua, IT; Barcelona, ES; Leuven, BE; Edmon-ton, Toronto, CA; Paris, FR; London, Birmingham, GB; Seattle, Dallas, Rochester, Phoenix, US)

12 .* A comparative study of cholestatic pruritus in primary biliary cirrhosis cohorts from USA, UK and Italy V .S . Hegade, G . Mells, C . Lammert, B . Juran, A . Lleo, M . Carbone, K . Lazaridis, P . Invernizzi, S . Kendrick, R . Sandford, G . Hirschfield, D .E .J . Jones (Newcastle upon Tyne, Cambridge, Birmingham, GB; Indianapolis, Rochester, US; Milan, IT)

13 . Are gastroenterologists and hepatologists ready for stratified therapy in primary biliary cirrhosis? A study of educational awareness L . Jopson, P . Peterson, E . Rudell, M . Corrigan, D .E .J . Jones (Newcastle upon Tyne, Birmingham, GB; New Jersey, US)

14 . Assessment of metabolic syndrome in patients with primary biliary cirrhosis M . Mahmoudi, N . Ben Mustapha, M . Amri, M . Serghini, M . Fekih, L . Kallel, S . Matri, J . Boubaker, A . Filali (Tunis, TN)

15 . Autoantibody status and histological variables influence biochemical response to treatment and long-term outcomes in Tunisian patients with primary biliary cirrhosis M . Mahmoudi, N . Ben Mustapha, M . Amri, R . Ben Jemaa, M . Fekih, L . Kallel, M . Serghini, S . Matri, J . Boubaker, A . Filali (Tunis, TN)

16 . Enhanced expression of hepatic fibroblast growth factor 19 (FGF19) is associated with suppression CYP7A1 and correlates with severity of the disease in primary biliary cirrhosis M . Milkiewicz, E . Wunsch, U . Wasik, J . Trottier, A . Kempinska-Podhorodecka, E . Elias, O . Barbier, P . Milkiewicz (Szczecin, Warsaw, PL; Quebec, CA; Birmingham, GB)

17 . CTLA-4 and TNF-α polymorphisms and concomitant autoimmune diseases in Slovenian patients with primary billiary cirrhosis K . Novak, M . Ribnikar, A . Markovic-Predan, K . Zaletel, A . Bicek, V . Dolzan (Ljubljana, SI)

18 . GP210 and/or SP100 autoantibodies in primary biliary cirrhosis: Predictors of cirrhosis/autoimmune (AIH) overlap syndrome? O . Taiwo, S . Mathew, J . Van Vlymen, A . Correa, J . Deacock, P . Berry, K . Cheent, H . Lewis, A . Ala (Guildford, Frimley, GB)

PSC

19 . Clinical features and outcome of CSP patients with IBD: A comparative single center experience M . Amri, L . Kallel, M . Mahmoudi, N . Ben Mustapha, M . Serghini, M .M . Feki, S . Matri, M . Fekih, J . Boubaker, A . Filali (Tunis, TN)


11

20 . The bile acid intermediate c4 and serum bile acid levels are potential mechanistic endpoints in human cholestatic trials: The ATRA + UDCA pilot in PSC D .N . Assis, K .D .R . Setchell, J .L . Boyer (New Haven, Cincinnati, US)

21 . Changing pattern of indications and results of endoscopic retrograde cholangio-pancreatography in patients with primary sclerosing cholangitis A . Ouakaa-Kchaou, D . Trad, N . Bibani, H . Elloumi, A . Kochlef, D . Gargouri, J . Kharrat (Tunis, TN)

22 . Transplant-free survival is PSC is influenced by azathioprine, steroids and the presence of inflammatory bowel disease F . Saffioti, P . Manousou, S . Aspite, D . Chatzidis, A . Marshall, M . Pinzani, D . Thorburn (London, GB)

23 . Primary sclerosing cholangitis: A review of clinical cases M . Stambolyiska, K . Ivanov, D . Gancheva, I .A . Kotzev (Varna, BG)

24 .* VAP-1 is elevated in PSC, correlates with clinical outcome and exhibits amine oxidase activity in a substrate-dependent manner P . Trivedi, J . Tickle, G . Hirschfield, C .J . Weston, D .H . Adams (Birmingham, GB)

25 .* Connecting liver and gut in PSC: CCL25 expression is upregulated in colitis, correlates with inflammatory activity and facilitates effector CCR9+ lymphocyte recruitment P . Trivedi, T . Bruns, S . Ward, M . Mai, C . Schmidt, G . Hirschfield, C .J . Weston, D .H . Adams (Birmingham, GB; Jena, DE)

26 . Sulphotransferase2A1 (SULT2A1) is not adequately induced in patients with primary sclerosing cholangitis U . Wasik, E . Wunsch, M . Milkiewicz, A . Kempinska-Podhorodecka, E . Elias, P . Milkiewicz (Szczecin, Warsaw, PL; Birmingham, GB)

27 .* Serum autotaxin is associated with pruritus and severity of liver disease in primary sclerosing cholangitis E . Wunsch, A . Kremer, J . Trottier, M . Krawczyk, O . Barbier, F . Lammert, P . Milkiewicz (Szczecin, PL; Erlangen, DE; Quebec, CA; Homburg, DE)

AIH

28 .* Celiac disease, cryptogenic hypertransaminasemia and autoimmune hepatitis S . Akbulut, K .C . Deger, A .S . Senger, S . Yol (Istanbul, TR)

29 . Impact of age on natural history and response to treatment of autoimmune hepatitis M . Amri, L . Kallel, M . Mahmoudi, M . Serghini, N . Ben Mustapha, M . Fekih, S . Matri, J . Boubaker, A . Filali (Tunis, TN)

30 .* Autoimmune hepatitis: A challenging disease deserving of specialist care G .D . Appanna, M .A . Czajkowski, A .D . Yeoman (Newport, GB)

31 . Autoimmune hepatitis and the polyglandular autoimmune syndrome type 1 in 12-year-old girl K . Bak-Drabik, J . Porebska, A . Chobot, A . Krzywicka (Zabrze, PL)


12

32 . Celiac disease-associated autoimmune liver and thyroid diseases in a pediatric population from Western Romania O .-A . Belei, L . Olariu, M . Pop, O . Gradinaru-Tascau, T . Marcovici, O . Marginean (Timisoara, RO)

33 .* Autoimmune hepatitis and cryptogenic hypertransaminasemia among Romanian children with celiac disease O .-A . Belei, L . Olariu, A . Craciun, T . Marcovici, O . Gradinaru-Tascau, I . Simedrea, O . Marginean (Timisoara, RO)

34 . Prevalence of hepatitis B virus infection in patients with autoimmune hepatitis in a Tunisian patient population R . Ben Jemaa, M . Fekih, W . Ben Ameur, S . Matri, M . Serghini, J . Boubaker, L . Kallel, A . Filali (Tunis, TN)

35 . Biomarkers of oxidative stress and their implication in autoimmune hepatitis M .C . Bezna, C . Deliu, M . Bezna, O . Diaconu, N . Gard, M . Balasoiu (Craiova, RO)

36 . Celiac disease with autoimmune hepatitis; a case report A .H . Cekin, S . Uyar, B . Yesil, A .G . Sumer, F . Harmandar, G .Z . Gorgulugil (Antalya, TR)

37 . A 20-year experience in the treatment of autoimmune hepatitis V . Chaloska-Ivanova, V . Serafimoski, M . Miloshevski, M . Genadieva-Dimitrova, B . Todorovska (Skopje, MK)

38 . Bone mineral density in Tunisian patients with autoimmune hepatitis M . Cheikh, H . Romdhane, R . Ennaifer, H . Ben Nejma, W . Bougassas, N . Bel Hadj (Tunis, TN)

39 . Clinical features of autoimmune hepatitis in the elderly . Results of a Tunisian study M . Cheikh, H . Romdhane, R . Ennaifer, H . Ben Nejma, W . Bougassas, N . Bel Hadj (Tunis, TN)

40 . Concurrent autoimmune diseases in patients with autoimmune hepatitis . Results of a Tunisian survey M . Cheikh, H . Romdhane, R . Ennaifer, H . Ben Nejma, W . Bougassas, N . Bel Hadj (Tunis, TN)

41 . Etanercept-induced fever in autoimmune hepatitis E . Ergin (Manisa, TR)

42 . Autoimmune and cholestatic liver disorders E . Ergin (Manisa, TR)

43 . Autoimmune diseases are common in patients with autoimmune hepatitis F . Gundling, T . Leimbach, A . Nerlich, W . Schepp (Munich, DE)

44 . The primary biliary cirrhosis (PBC)-autoimmune hepatitis (AIH) overlap syndrome - A single center Tunisian experience M . Hafi, R . Ben Jemaa, M . Fekih, K . Agar, N . Ben Mustapha, M . Serghini, J . Boubaker, L . Kallel, A . Filali (Tunis, TN)


13

45 . Efficacy of alternative immunosuppressive strategy to induce and maintain remission in patients with autoimmune hepatitis V . Hejda, J . Kozeluhova, K . Balihar, H . Mirka, O . Daum (Pilsen, CZ)

46 . Upper gastrointestinal muscosal lesions and Helicobacter pylori infection in au-toimmune liver disease E . Kasap, U . Demirci, T . Buran, H . Yüceyar (Manisa, TR)

47 . Combined liver injury (overlap syndrome), particular qualities of flow N .V . Kharchenko, G . Anokhina, V . Kharchenko, D . Janelidze (Kiev, UA)

48 . Epidemiological and clinical characteristics of autoimmune hepatitis in Albania B . Kraja, I . Akshija, D . Vathi, F . Kraja, A . Babameto (Tirana, AL)

49 . Epidemiological, clinical and therapeutic characteristics of autoimmune hepatitis . Results of a Tunisian study M . Labbane, K . Torjmane, S . Zarrouk, Y . Bouteraa, S . Ouerdiane (Bizerta, TN)

50 . Ultrastructural features of hepatic fibrogenesis in children with autoimmune hepatitis J .M . Lotowska, M .E . Sobaniec-Lotowska, D .M . Lebensztejn, S . Sulkowski (Bialystok, PL)

51 .* Myeloid-derived suppressor cells and the liver microenvironment in autoimmune liver disease X . Ma, H . Zhang, Z . Bian, Q . Wang, P . Invernizzi, M .E . Gershwin (Shanghai, CN; Rozzano, IT; Davis, US)

52 . The most common rheumatic diseases in patients with autoimmune liver disease in a Tunisian center M . Mahmoudi, N . Ben Mustapha, M . Amri, R . Ben Jemaa, M . Fekih, L . Kallel, M . Serghini, S . Matri, J . Boubaker, A . Filali (Tunis, TN)

53 .* The role of repeat liver biopsies in autoimmune hepatitis: Clinical practice and outcomes S . Mathew, R . Narang, M . Pericleous, A . Ramu, P . Berry, K . Cheent, H . Lewis, G . Kousparos, A . Ala (Frimley, GB)

54 . Correlations between serologic markers, clinical presentation and response to treatment in patients with autoimmune hepatitis at a tertiary referral center R . Maxim, A . Chelaru, E . Sarca, A . Plesa (Iasi, RO)

55 . Aspartate aminotransferase to platelet ratio index for fibrosis and cirrhosis evaluation in autoimmune liver diseases R . Maxim, A . Trifan, O . Stoica, A . Plesa, C . Stanciu (Iasi, RO)

56 . Autoimmune hepatitis/primary biliary cirrhosis (AIH/PBC)-overlap syndrome (OS) and hepatic carcinogenesis K . Pavlov, J . Genov, R . Mitova, D . Sotirov, I . Terziev, B . Vladimirov, D . Dimitrov, M . Spasov, G . Taneva, E . Pophristova (Sofia, BG)

57 . Angiotensin converting enzyme for non-invasive assessment of liver fibrosis in autoimmune hepatitis T . Pürnak, C . Efe, Y . Beyazit, E . Özaslan (Ankara, Batman, Canakkale, TR)


14

58 . Ultrastructural characteristics of sinusoidal Kupffer cells/macrophages in pediatric autoimmune hepatitis – The analysis of 17 cases M .E . Sobaniec-Lotowska, J .M . Lotowska, D .M . Lebensztejn, S .B . Lotowska (Bialystok, PL)

59 . Therapeutic strategies in autoimmune hepatitis: Results from daily practice C . Teixeira, D . Trabulo, S . Ribeiro, C . Martins, C . Cardoso, I . Cremers, A .L . Alves, A .P . Oliveira (Setubal, PT)

60 . Use of tacrolimus in patients with treatment resistant type 1 autoimmune hepatitis N .N . Than, C . Wiegard, K . Fussel, J . Mann, G . Hirschfield, A .W . Lohse, D .H . Adams, C . Schramm, Y .H . Oo (Birmingham, GB; Hamburg, DE)

61 . Serological differential diagnosis of autoimmune liver diseases by line immunoasssay for parallel detection of 9 different autoantibodies T . Velikova, E . Ivanova-Todorova, K . Toumangelova-Yuzeir, L . Kancheva, D . Kyurkchiev, B . Tomov, A . Aleksiev, R . Nikolov, L . Mateva-Vladimirova (Sofia, BG)

62 . Infliximab leading to autoimmune hepatitis: An increasingly recognized side effect B . Yilmaz, E .C . Roach, S . Koklu (Ankara, TR)

63 . The use of azathioprine metabolites in monitoring patients with autoimmune hepatitis F . Yousuf, P . Richardson, T . Cross, I . Patanwala (Liverpool, GB)

64 . Diagnostic value of autoantibodies to asialoglycoprotein receptor (ASGPR) in children with autoimmune hepatitis O . Zaja, A . Tesija Kuna, A . Jaklin Kekez, I . Vukasovic, N . Vrkic (Zagreb, HR)

MISCELLANEOUS

65 . Perioperative and long-term morbi-mortality associated with surgery for ileocecal Crohn‘s disease N . Ben Mustapha, M . Mahmoudi, M . Bejaoui, A . Laabidi, M . Serghini, L . Kallel, M . Fekih, J . Boubaker, A . Filali, A . Makni, W . Rebai, S . Ayadi, M . Jouini, M . Kacem, Z . Ben Safta (Tunis, TN)

66 . Liver abnormalities in patients with primary Sjögren‘s syndrome A . Demirezer Bolat, Ö . Tayfur Yürekli, S . Erten, F . Ebru Akin, M . Tahtaci, O . Ersoy (Ankara, TR)

67 . Assessment of coagulation status in cirrhotic patients M . Fekih, A . Laabidi, H . Baccouche, K . Agar, J . Boubaker, N . Ben Romdhane, L . Kallel, A . Filali (Nabeul, Tunis, TN)

68 . Anomalies of bone tissue metabolism during cirrhosis M . Fekih, A . Laabidi, R . Ben Jemaa, N . Ben Mustapha, S . Matri, M . Serghini, J . Boubaker, L . Kallel, A . Filali (Tunis, TN)

69 . Hepatobiliary manifestations in Tunisian inflammatory bowel disease patients L . Hamzaoui, M . Mahmoudi, S . Elbouchtili, M . Medhioub, H . Ezzine, M .M . Azouz (Tunis, Nabeul, TN)


15

70 . Does the implementation of a new research-focussed clinical care model improve research activity in autoimmune liver disease? K . Houghton, S . Ducker, L . Jopson, D . Jones (Newcastle upon Tyne, GB)

71 . Epidemological and clinic-pathological survey of patients with autoimmune diseases of the liver in the Austrian Federal State Salzburg: Experience of a single center R . Illig, E . Klieser, W . Tränkenschuh, T . Kiesslich, F . Berr, D . Neureiter (Salzburg, AT)

72 . Impact of viral etiology on hemostatic state in cirrhotic patients A . Laabidi, A . Filali, H . Baccouche, L . Kallel, N . Ben Mustapha, N . Ben Romdhane, M . Fekih, M . Serghini, J . Boubaker (Tunis, TN)

73 . Autoimmune disorders in celiac disease M . Mahmoudi, N . Ben Mustapha, M . Amri, M . Serghini, L . Kallel, M . Fekih, S . Matri, J . Boubaker, A . Filali (Tunis, TN)

74 . The role of ultraviolet phototherapy in treatment of cholestasis-induced pruritus D . Neagoe, S . Ianosi, A . Farmazon, D . Toma, A . Fetoiu, T . Ciurea (Craiova, RO)

75 .* Presepsin as a new biomarker for old expectations in the diagnosis and prognosis of bacterial infection in cirrhosis M . Papp, T . Tornai, D . Tornai, Z . Vitalis, I . Tornai, P .L . Lakatos, P . Antal-Szalmas (Debrecen, Budapest, HU)

76 . Hypereosinophilic autoimmune liver disease: A report of three unusal cases M . Pericleous, S . Mathew, M . Lloyd, P . Berry, H . Lewis, K . Cheent, A . Ramu, A . Ala (Frimley, Guildford, GB)

77 .* Soluble CD163 (sCD163) is a marker of infection in patients with cirrhosis and acute decompensation and an independent predictor of the short-term mortality T . Tornai, D . Tornai, N . Sipeki, I . Foldi, T . Dinya, Z . Vitalis, P . Antal-Szalmas, I . Tornai, M . Papp (Debrecen, HU)

78 . Attitude to and practice of diagnostic paracentesis on the general medical take: Room for improvement? L . Tyson, K . Patel, S . Mann (London, GB)

* = Posters of Distinction


16

List of Speakers, Moderators and Scientific Organizers

Prof. Dr. David H. AdamsInstitute of Clinical SciencesLiver Research LaboratoriesQueen Elizabeth HospitalBirmingham B15 2THGreat Britaind .h .adams@bham .ac .uk

Prof. Dr. Ulrich BeuersDepartment of Gastroenterologyand Hepatology, G4-216Tytgat Institute for Liverand Intestinal ResearchUniversity of AmsterdamMeibergdreef 91105 AZ AmsterdamThe Netherlandsu .h .beuers@amc .uva .nl

Dr. Gerd BoumaDepartment of GastroenterologyVrije Universiteit Medical CenterDe Boelelaan 11181081 HV AmsterdamThe Netherlandsg .bouma@vumc .nl

Prof. Dr. Olivier Chazouillères Service d’Hépatologie Hôpital Saint Antoine184, Rue du Faubourg St .-Antoine 75012 Paris Franceolivier .chazouilleres@sat .aphp .fr

Prof. Dr. Helena Cortez-PintoDepartamento de GastroenterologiaHospital Santa MariaAv . Prof . Egas Moniz1649-001 LisbonPortugalhlcortezpinto@netcabo .pt

Dr. Luca FabrisDepartment of Molecular MedicineUniversity of Padua School of MedicineVia A . Gabelli, 6335121 PadovaItalyluca .fabris@unipd .it

Prof. Dr. Andre FrankeKlinische MolekularbiologieChristian-Albrechts-UniversitätSchittenhelmstrasse 1224105 KielGermanya .franke@mucosa .de

Prof. Dr. Pere GinèsLiver UnitUniversity of BarcelonaHospital Clinicc/ Villarroel no . 17008036 BarcelonaSpainpgines@clinic .ub .es

Prof. Dr. Dermot C. GleesonLiver UnitSheffield Teaching HospitalsSheffield Great Britaindermot .gleeson@sth .nhs .uk

Dr. Michael A. HeneghanInstitute of Liver StudiesNHS Foundation Trust King‘s College Hospital Denmark HillLondon SE5 9RSGreat Britainmichael .heneghan@nhs .net

PD Dr. Johannes HerkelMedizinische Klinik IUniversitätsklinikum EppendorfMartinistr . 5220251 HamburgGermanyjherkel@uke .uni-hamburg .de


17

Dr. Gideon HirschfieldUniversity of BirminghamCenter of Liver ResearchInstitute of Biomedical ResearchP .O . Box 363Birmingham B15 2TTGreat Britaing .hirschfield@bham .ac .uk

Dr. Pietro InvernizziLiver Unit and Center for Autoimmune Liver DiseasesHumanitas Clinical and Research CenterVia Manzoni 5620089 Rozzano, MilanItaly pietro .invernizzi@humanitas .it

Dr. Peter JepsenDepartment of Clinical EpidemiologyAarhus University HospitalNorrebrogade 448000 AarhusDenmarkpj@clin .au .dk

Prof. Dr. David E. J. JonesCenter for Liver ResearchUniversity of NewcastleSchool of Medicine3rd floor, William Leech Bldg .Framlington PlaceNewcastle upon Tyne NE2 4HHGreat Britaindavid .jones@newcastle .ac .uk

Dr. Tom H. KarlsenMedical DepartmentNorwegian PSC Res . Ctr .University of OsloRikshospitalet0027 OsloNorwaytomhk@ulrik .uio .no

Dr. Andreas E. KremerGastroenterologie, Pneumologie und EndokrinologieMedizinische Klinik IFriedrich-Alexander-Universität ErlangenUlmenweg 1891054 ErlangenGermany andreas .kremer@uk-erlangen .de

Dr. Rodrigo LiberalInstitute of Liver StudiesKing‘s College London School of MedicineDenmark HillLondon SE5 9RSGreat Britainrodrigo .liberal@kcl .ac .uk

Prof. Dr. Ansgar W. LohseMedizinische Klinik IUniversitätsklinikum EppendorfMartinistr . 5220251 HamburgGermanyalohse@uke .de

Dr. Luigi MuratoriDepartment of Medical and Surgical Sciences Alma Mater Studiorum - University of BolognaSant‘Orsola-Malpighi Hospital Pavilion 11 via Massarenti, 9 40138 Bologna Italyluigi .muratori@unibo .it

Prof. Dr. Albert ParésLiver UnitUniversity of BarcelonaHospital Clinicc/ Villarroel no . 17008036 BarcelonaSpainapares@clinic .ub .es


18

Dr. Cyriel Y. PonsioenDepartment of Gastroenterology and Hepatology Academic Medical Center AmsterdamP .O . Box 227001100 DE AmsterdamThe Netherlandsc .y .ponsioen@amc .uva .nl

Prof. Dr. Raoul PouponService d‘Hépato-Gastro-EntérologieHôpital Saint-Antoine184, rue du Faubourg St . Antoine75571 ParisFranceraoul .poupon@gmail .com

Prof. Dr. Christoph SchrammMedizinische Klinik IUniversitätsklinikum EppendorfMartinistr . 5220251 HamburgGermanycschramm@uke .de

Dr. Dina G. TiniakosInstitute of Cellular MedicineFaculty of Medical SciencesNewcastle UniversityWilliam Leech Building4th Floor, Room M4-143Framlington PlaceNewcastle upon Tyne NE2 4HH Great Britaindina .tiniakos@ncl .ac .uk

Prof. Dr. Michael TraunerMedizinische Universität WienKlinische Abteilung fürGastroenterologie & HepatologieWähringer Gürtel 18-201090 WienAustriamichael .trauner@meduniwien .ac .at

Dr. Henk R. van BuurenDepartment of Gastroenterologyand HepatologyRoom Ha-203Erasmus MCPO Box 20403000 CA RotterdamThe Netherlandsh .vanbuuren@erasmusmc .nl


19

Congress OfficeDuring the Falk Symposium 197

Estoril Centro de Congressos Telephone: +49 (0)175/7795327Avenida Amaral2765-192 EstorilPortugal

Opening Hours:Thursday, May 7, 2015 16 .00 – 21 .00 hFriday, May 8, 2015 8 .00 – 18 .00 hSaturday, May 9, 2015 9 .00 – 14 .00 h

Congress FeesScientific program of the Falk Symposium 197 € 200 .00Students and residents € 100 .00

* * *OR* **

Day ticket € 120 .00Students and residents € 60 .00

Employees of pharmaceutical companies and their guestsFalk Symposium 197 € 600 .00

The congress fees include:- Welcome Evening on May 7, 2015- Refreshments during coffee breaks- Lunch on May 8 and 9, 2015- A copy of the abstract volume


20

Admission to Scientific EventsFor admission to scientific events your name badge should be clearly visible .

Congress ReportThe official congress report of the Falk Symposium 197 “Autoimmune Diseases of the Liver” will be published in English in the second half of 2015 by Karger, Switzerland . Orders for this book at a reduced subscription price of € 35 .00 can be placed at the Congress Office during the congress in Lisbon .

AirportLisbon International Airport → 30 km from congress venuehttp://www .lisbon-airport .com/

Symposia and workshopsOver 270 with more than 130,000 international participants since 1967

Continuing medical education seminarsOver 16,000, attended by more than 1.3 million physicians and patientsin Germany alone

Comprehensive literature servicefor healthcare professionals and patientsMore than 200 publications

Leinenweberstr. 579108 FreiburgGermanyTel +49 (0)761/1514-0Fax +49 (0)761/1514-321

www.falk-foundation-symposia.orgsymposia@falk-foundation-symposia.org

Scientific Dialoguein the Interest of

Therapeutic Progress

Falk Foundation e.V.

Image_A5_2c_engl_Symposia_3-15.indd 1 26.03.15 10:09113988_Falk_Lissabon_Symp197_Prog_Inhalt.indd 20 14.04.15 15:15

Symposia and workshopsOver 270 with more than 130,000 international participants since 1967

Continuing medical education seminarsOver 16,000, attended by more than 1.3 million physicians and patientsin Germany alone

Comprehensive literature servicefor healthcare professionals and patientsMore than 200 publications

Leinenweberstr. 579108 FreiburgGermanyTel +49 (0)761/1514-0Fax +49 (0)761/1514-321

www.falk-foundation-symposia.orgsymposia@falk-foundation-symposia.org

Scientific Dialoguein the Interest of

Therapeutic Progress

Falk Foundation e.V.

Image_A5_2c_engl_Symposia_3-15.indd 1 26.03.15 10:09113988_Falk_Lissabon_Symp197_Prog_Inhalt.indd 21 14.04.15 15:15

Program

P197

e 1-

4/2

015

/90

0 St

ü

General Information:

FALK FOUNDATION e.V.Leinenweberstr. 579108 FreiburgGermany

Congress DepartmentTelephone: +49(0)761/1514-0Telefax: +49(0)761/1514-359E-Mail: [email protected]

Falk Symposium 197



CME credits 9

Awarded with

113988_Falk_Lissabon_Symp197_Prog_UG.indd 1 14.04.15 15:07

germany program - drfalkpharma.com · beuers, amsterdam; a . parés, barcelona 16.30 fatigue in pbc...

Documents